Clinical trial
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
NCT00026169 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00026169 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure |
| Official title | A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis, pharmacological study |
| Enrollment | 69 |
| Start date | Sep 1, 2001 |
| Primary completion | Apr 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: